🔘 Out on The Lancet Oncology Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

#BladderCancer #Immunotherapy Andrea Necchi Ashish M. Kamat, MD, MBBS Petros Grivas…

Kudos to Andrea Necchi Valentina Tateo on leading this consensus recommendation on use of NGS in pts with urothelial ca! Honored to be panel member for this highly productive Ospedale San Raffaele retreat with esteemed experts!
Philippe spiess Neeraj Agarwal, MD, FASCO Ashish M. Kamat, MD, MBBS ylt #JeffRoss

Jus had the privilege of meeting Ashish M. Kamat, MD, MBBS in person!! It was special. His contributions to #NMIBC research are monumental. Grateful for his insights perspective and in his key role in promoting patient advocacy groups Rebecca Johnson Bladder Cancer Advocacy Network IBCG associazionepalinuro

Thanks Bladder Cancer Advocacy Network we are getting ready for annual #bladdercancer walk in Seattle Lake Sammamish on May 18! Everyone is welcome:
secure2.convio.net/bcani/site/TR/…

Betsy Koehne Minas Economides, MD Sarah P. Psutka MD MS Prof Param Mariappan Dimitra Bakaloudi MD, MS Stephanie Chisolm, PhD Jonathan L Wright Ashish M. Kamat, MD, MBBS OncoAlert

Congratulations Patrizia!
Was great to see you in Madrid and hear your views on improving QOC for our patients

This may be the most awesome thing that we have ever seen on Twitter. We are so grateful and thank you to everyone, especially Prof Param Mariappan Ashish M. Kamat, MD, MBBS Shilpa Gupta Petros Grivas Janet Kukreja Amanda Myers Andrea Necchi Sarah P. Psutka MD MS Jeremy Teoh Jennifer Regala Yüksel Ürün…

The design of KN57 and approval of pembrolizumab by the FDA for BCG-unresponsive HR NMIBC set the stage and provided valuable lessons for the current crop of clinical trials

Congrats to investigators & thank you to patients for their participation in research!

#BladderCancer …

#BOND -003 Phase 3 Results: Revolutionizing #BladderCancer treatment for high-risk BCG-unresponsive #NMIBC . Mark Tyson Mayo Clinic joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center in this great discussion > bit.ly/48MKoGV CG Oncology, Inc.

#SunRISe -3 trial: TAR-200 with or without cetrelimab vs BCG for BCG-naive HR #NMIBC . Sam S. Chang MD, MBA Vanderbilt Urology and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center discuss insights from this trial which could shift treatment paradigms, offering a promising alternative to BCG > bit.ly/44A2gUA

Thrilling debate on micropapillary NMIBC treatment in a fully-packed room for the rapid-fire debate on BC: upfront radical cystectomy (Ashish M. Kamat, MD, MBBS) vs. intravesical therapy (@BenjaminPradere) #EAU24

Video in @Urotoday: Racial Differences in Bladder Cancer Detection Using Blue Light Cystoscopy: A Multi-Center Study, with @Urodocash and Sia Daneshmand, M.D.. Click to watch the video: urotoday.com/video-lectures…

So proud of this crew 🤩

Thanks for sharing Ashish M. Kamat, MD, MBBS the APPs have indeed major role & huge contributions in patient care, research, education, outreach, etc. Amer. Urol. Assn. MD Anderson Cancer Center
Fred Hutchinson Cancer Center UW Urology OncoAlert UroToday.com Sarah P. Psutka MD MS Dimitra Bakaloudi MD, MS Dr. Bishoy M. Faltas Shilpa Gupta Pavlos Msaouel

𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Prof Param Mariappan Ashish M. Kamat, MD, MBBS Shilpa Gupta Petros Grivas IBCG Bladder Cancer Advocacy Network Janet Kukreja Amanda Myers Andrea Necchi Sarah P. Psutka MD MS Jeremy Teoh Jennifer Regala Yüksel Ürün OncLive.com Love this! #NoOneWalksAlone !

IBCG Karima Oualla, MD,MSc Shilpa Gupta Ashish M. Kamat, MD, MBBS Amanda Myers Janet Kukreja Petros Grivas Patrick Hensley, MD Sima Porten Amer. Urol. Assn. So proud to be a part of this group!

A great walk to support #Bladderca by
@IBCG_BladderCA@AmerUrological
#AUA -IBCG #AUA 24 Thx Ashish M. Kamat, MD, MBBS
for coordinating! Prof Param Mariappan
Petros Grivas Sia Daneshmand, M.D.
Sarah P. Psutka MD MS Roger Li Patrick Hensley, MD
Joan Palou Redorta World Bladder Cancer Patient Coalition
@bean_chisolm Karima Oualla, MD,MSc Carme Mir

Optimal #TURBT : Do skilled urologists really need to perform reTUR for all HG patients? Neal Shore moderates a debate between Jeremy Teoh CUHK Medicine and Badrinath Konety, MD, MBA Allina Health. #AUA24 coverage with Zach Klaassen > bit.ly/4boKdTu #AUAIBCGBladderCancerForum Ashish M. Kamat, MD, MBBS

The microbiome's impact on the immunotherapy of genitourinary cancers. Join Sumanta K. Pal, MD, FASCO City of Hope and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center as they discuss foundational research into the influence of the gut #microbiome on #GUCancers and immunotherapy > bit.ly/3HPHdCR

Can we settle the debate on PLND in radical cystectomy? John Taylor moderates Seth Lerner and Sia Daneshmand, M.D.. #AUA24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3JR4xkB Ashish M. Kamat, MD, MBBS IBCG #BladderCancerForum Keck Medicine of USC BCMHouston

Management of recurrent low-grade intermediate-risk bladder tumors. Sarah P. Psutka MD MS and Prof Param Mariappan #AUA24 #debate . Written coverage by Zach Klaassen > bit.ly/3JQVpMZ IBCG #BladderCancerForum Ashish M. Kamat, MD, MBBS